Michelle is an experienced pharmaceutical executive with more than 20 years in the industry spanning both commercial and research & development (R&D) responsibilities. Prior to Alltrna, Michelle served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology, where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts resulting in a doubling of long-term portfolio value for the franchise. Previous to Novartis, Michelle was a senior leader at AstraZeneca and as Global Franchise Head in Hematology, she was critical in launching multiple indications worldwide for CALQUENCE®. Prior to this, Michelle was Head of US Oncology, where she led the business through dramatic growth in team and revenue through eight-plus product launches. Michelle is a wife and mother to three children and is a member of the rare disease community. She serves on the Board for the non-profit organization Rare Disease Renegades, a purpose that fuels her passions both personally and professionally. For her role in breaking new ground in biopharma R&D and her patient advocacy work, Michelle has been honored with the following recognitions: Endpoints Women Leading BioPharma R&D, Fierce 50, PharmaVoice 100, and In Vivo’s Rising Leaders in Life Sciences.